MEI Pharma (MEIP) versus Its Competitors Head to Head Analysis
MEI Pharma (NASDAQ: MEIP) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare MEI Pharma to similar businesses based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.
This table compares MEI Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|MEI Pharma Competitors||-5,441.68%||-162.70%||-35.92%|
This table compares MEI Pharma and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MEI Pharma||$23.25 million||$2.67 million||-39.33|
|MEI Pharma Competitors||$290.27 million||$35.99 million||60.31|
MEI Pharma’s peers have higher revenue and earnings than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
MEI Pharma has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, MEI Pharma’s peers have a beta of 5.84, indicating that their average share price is 484% more volatile than the S&P 500.
This is a breakdown of current recommendations for MEI Pharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|MEI Pharma Competitors||1134||3426||11925||240||2.67|
MEI Pharma currently has a consensus price target of $6.75, suggesting a potential upside of 186.02%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.60%. Given MEI Pharma’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MEI Pharma is more favorable than its peers.
Insider and Institutional Ownership
23.2% of MEI Pharma shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.3% of MEI Pharma shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MEI Pharma peers beat MEI Pharma on 7 of the 13 factors compared.
About MEI Pharma
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.